Kornimate/medical-research-clean huggingface dataset:
longitudinal cognitive assessment by boca

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Vascular Dementia; Frontotemporal Dementia; Parkinson Disease; Multiple Sclerosis; TBI

Summary: the boston cognitive assessment (boca) is a self-administered online test intended for longitudinal cognitive monitoring. boca uses random not-repeating tasks to minimize learning effects. boca was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.

the boston cognitive assessment (boca) is a self-administered online test intended for longitudinal cognitive monitoring. boca uses random not- repeating tasks to minimize learning effects. boca was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals. boca includes eight subtests in the following domains: memory/immediate recall, memory/delayed recall, executive function/ visuospatial, executive function/ mental rotation, attention, mental math, language/prefrontal synthesis, and orientation. the maximum total score is 30. higher score indicates better cognitive performance. after boca is completed, the domain scores and total score are provided immediately. users will also receive an email with the link to the full report with progress charts. the boca evaluation can help doctors figure out if an underlying condition is causing a patient's cognitive decline. many treatable conditions such as sleep disorders, mood problems, heavy metal accumulation, as well as lack of movement and social interactions can affect memory and thinking. our goal is to reduce barriers for patients to receive the testing that may benefit their treatment and health through the use of digital technology.

Eligibility criteria:
inclusion criteria: age 50 or older exclusion criteria: younger than 50 years
diabetes outcomes and nurse case manager study

Conditions: Type 2 Diabetes

Summary: this study will examine whether patients with diabetes who are either 1) newly discharged from hospital or 2) referred to an endocrinologist for management will have better diabetes outcomes when their care is managed primarily by a dedicated case manager (intervention) than by an endocrinologist (standard care) after 6 months of treatment.

the study will be a randomized-control trial recruiting patients with type 2 diabetes in a specialty care setting from two sources: 1. referred by family physicians with inadequate glycemic control likely requiring exogenous insulin therapy 2. referred by medical staff at vancouver general hospital or st. paul's hospital during in-patient care \& about to be discharged (appendix 1). patients who meet the inclusion criteria will be randomly assigned into either the ncm group or sc group.

Eligibility criteria:
inclusion criteria: * type 2 diabetes * a1c \> 8.0 or * bp \> 140/90 or * ldl cholesterol \> 2.0 (72 mg/dl) exclusion criteria: * inability to speak english or to be assisted by somebody fluent in english

Keywords: type 2 diabetes outcomes case management
the effect of kombucha on blood sugar levels in humans

Conditions: Glucose; Glucose Metabolism Disorders (Including Diabetes Mellitus); Blood Sugar; High

Summary: as a phase 0 clinical trial, we will learn how kombucha influences glucose metabolism in humans.

consumption of kombucha, a fermented tea beverage, has been promoted for a wide range of health benefits. however, a systematic literature review (kapp \& sumner, 2019) revealed a lack of evidence for human health benefit. despite the lack of evidence, u.s. retail sales of kombucha and other fermented beverages have increased 37.4% in 2017, and kombucha is the fastest growing product in the functional beverage market. as a phase 0 clinical trial, we will learn how kombucha influences glucose metabolism in humans. we plan for 20 subjects to take part in this study. this is a randomized-controlled counter-balanced study design. subjects will be asked to complete 4 in-person visits over 2 months time (twice per month). at the first visit, subjects will be randomized into one of four groups. at each subsequent visit, subjects will be randomized into one of the remaining groups until they have completed each arm. arms (at least 5 subjects in each arm, minimum total=20 subjects) 1. intervention group 1: commercial kombucha: drink 8oz kombucha 2. intervention group 2: brewed kombucha: drink 8oz kombucha 3. control group: drink 8oz tea (the same type as used to brew the kombucha) 4. control group 2: drink 8oz tap water

Eligibility criteria:
inclusion criteria: * men or women ages 30-65 years old * english-speaking * have transportation to campus * overweight (bmi \>= 25 kg/m2) or obese (bmi \>=30 kg/m2) exclusion criteria: * currently use any type of nicotine product * a diagnosis of any of the following: * diabetes (type 1 or 2) * cancer * copd * chronic alcoholism * peripheral vascular disease * autoimmune disease * chronic kidney disease * pregnant or breastfeeding * prescribed medication for insulin, glucose-lowering drugs, or steroids, such as prednisone * have routinely taken prebiotic or probiotic supplements in the past 3 months * have routinely consumed any of the following more than one time per week in the past month: kombucha, kefir, yogurt, kimchi, cottage cheese, raw apple cider vinegar (with the "mother"), sauerkraut, kvass.

Keywords: kombucha kombucha tea tea fermented food
prospective evaluation of lymphoedema among patients with gynaecological cancer

Conditions: Female Genital Diseases; Ovarian Cancer; Cervical Cancer; Endometrial Cancer; Vulval Cancer

Summary: this project will conduct a prospective, longitudinal, observational cohort study to assess the onset and incidence of lymphoedema, as well as investigate factors associated with its development among women newly diagnosed with gynaecological cancers in 2008 to 2011.

pathological swelling of the lower limbs (lymphoedema) is widely accepted to be a common consequence of treatment for gynaecological cancer. it is both a serious and debilitating complication, associated with significant morbidity, which impacts physically and emotionally on otherwise healthy women. lymphoedema can also affect patients' ability to earn an income, especially if their work requires prolonged periods of standing or walking. the causes of lymphoedema are largely unknown with clinical data scarce regarding its onset time and incidence after gynaecological cancer treatment. the following hypotheses will be tested to address the aims of the project: 1. at least 20% of patients will develop lower-limb lymphoedema following gynaecological cancer treatment. 2. patient's age, as well as their body mass index (bmi), area of residence, degree of physical exercise, type of disease (uterine, cervical, ovarian, vulval/vaginal cancer; benign disease), mode of treatment (extent of lymph node dissection, radiotherapy, chemoradiation) and delay in wound healing are independent risk factors for lower-limb lymphoedema. 3. patients who develop lymphoedema after gynaecological cancer treatment, will experience increased pain, lower quality of life (including worse body-image), and decreased sexual \& financial well-being, compared to those who do not develop lymphoedema. 4. there will be at least 10% difference in the incidence of lower-limb lymphoedema between patients treated for gynaecological cancer compared to benign diseases.

Eligibility criteria:
inclusion criteria: * patients scheduled for surgery of benign or malignant gynaecological diseases as determined jointly by the surgeon and the patient. * non-pregnant female patients. * over 18 years of age at time of surgery. * patients who understand the conditions of the study and are willing to participate for the length of the prescribed term of follow-up. * patients who are capable of, and have given, informed consent to their participation in the study. exclusion criteria: * patients with a pacemaker. * allergies against adhesive electrodes and extensive internal metal plates are ineligible for bis measurement.

Keywords: lymphoedema gynaecology oncology malignant benign incidence
assessment of response to neo-adjuvant chemotherapy for patients with a locally advanced breast cancer with 3d elastography (shear wave),

Conditions: Breast Neoplasms

Summary: assess the accuracy of the sequential measurements by 3d shear wave elastography (swe) for predicting histological response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.


Eligibility criteria:
inclusion criteria: * infiltrating breast cancer untreated and/or locally advanced (stages i (t1c), iia iib, iiia, iiib, iiic of uicc classification), whatever histological type. * neo-adjuvant chemotherapy decided.(anthracyclines, taxanes and, for tumors overexpressing human epidermal growth factor receptor 2 (her2) protein, targeted recombinant humanized monoclonal antibodies) * index tumor whose dimensions are between 10 to 50 mm. multifocality, and/or multicentricity and/or bilaterality accepted (maximum 2 tumors by breast et tumors well differentiated from each other). * patients aged at least 18 years old at diagnosis * full results conventional breast exams available and no reason to achieve mri breast exam * patient explanation given and consent information signed exclusion criteria: * pregnant or during lactation * personal history of ipsilateral breast cancer (ipsilateral recurrence or second cancer in the same breast). * patient carrier of cosmetic breast implants * person deprived of liberty or under guardianship * contraindication for receiving neo-adjuvant chemotherapy for any medical reason * inability to submit to medical monitoring of the trial for reasons of geography, social or psychological.

Keywords: locally advanced breast cancer neoadjuvant chemotherapy
the effect of prayer on dyspnea severity, anxiety and spiritual well-being in individuals with copd

Conditions: COPD

Summary: this study will be conducted in order to examine the effect of prayer to individuals with copd on the severity of dyspnea, anxiety and spiritual well-being experienced by patients.

this study will be conducted on people with copd. people with copd disease will be divided into two groups. the experimental group will be given a prayer lesson for a month. prayer listening will not be performed to the control group. at the end of one month, the severity of dyspnea, anxiety and spiritual well-being levels of people in both groups will be re-evaluated.

Eligibility criteria:
inclusion criteria: * 90 individuals (45 experiments, 45 controls) who can be contacted, who have agreed to participate in the study * who are literate, can speak turkish * who have not participated in a similar application of this study before * who have agreed to participate in the study after being informed about the research * are 18 years old and over, with a copd diagnosis will be taken exclusion criteria: * individuals with mental and hearing problems, who have lost a family member and someone close to them in the last year * who are using tranquilizers/antidepressants * who have experienced a traumatic situation such as divorce will be excluded from the sample.

Keywords: dyspnea spiritual goodness anxiety
interventions to facilitate working while depressed and anxious

Conditions: Work Capacity

Summary: the study compares the effects of two add-on interventions in primary care rehabilitation, on work ability and psychological health, in workers with common mental disorders. one intervention consists of a person-centered plan using work-directed treatment modules of occupational therapy and physical therapy, during 8 weeks. the other intervention consists of supported physical activity during 8 weeks. the primary outcome is work ability, measured by the work ability index and days on sick leave.

common mental disorders (cmd), including mild to moderate depression, anxiety disorders and exhaustion disorder, are a major cause of sick leave and work disability. compared to other disorders, work-related problems associated with cmd is sparsely explored. while recommended treatments, such as antidepressants or cognitive behavioral therapy have effects on psychiatric symptoms, the effect on work capacity is unclear, suggesting a need for alternative interventions. the aim of this study is to evaluate the effects of an add-on work-directed intervention in primary care rehabilitation, compared to a physical activity control, for persons with cmd. the goal of the experimental condition is to enhance the participant's ability to work by creating an individually tailored plan for self-management, supported by occupational and physical therapy techniques, such as structuring daily activities, stress management or body awareness techniques. enhancing self-management is the core of this intervention and also a new approach compared to earlier efforts to promote work capacity.

Eligibility criteria:
inclusion criteria: * unipolar depression or anxiety disorder according to the mini neuropsychiatric interview (dsm-5 criteria). * currently working to some extent, part time sick leave is accepted. exclusion criteria: * substance abuse according to the mini interview * high suicide risk according to the mini interview * psychotic symptoms according to the mini interview

Keywords: work capacity evaluation common mental disorders occupational therapy physical therapy modalities
reduced stent strategy versus conventional percutaneous coronary revascularization in patients presenting with stemi

Conditions: ST Elevation Myocardial Infarction

Summary: the objective is to compare a reduced stent strategy based on drug-coated balloon (dcb) percutaneous coronary intervention (pci) with conventional drug-eluting stent (des) coronary revascularization in patients presenting with st-segment myocardial infarction (stemi). randomization will be performed after successful culprit-lesion guidewire crossing and flow restoration. random allocation in a 1:1 fashion to one of the following strategies: * study group: reduced stent pci strategy (dcb-based) * control group: conventional pci strategy (des-based).


Eligibility criteria:
inclusion criteria: - patients presenting with stemi and indication to undergo ppci. exclusion criteria: * life expectancy \<1 year due 1 to non-cardiac disease. * inability to provide informed consent. * cardiogenic shock. * left ventricular ejection fraction \<15%. * left main disease. * stent thrombosis * patients with prior bypass graft lesions requiring pci (culprit or non culprit lesions). * patients with chronic total occlusions. * untreatable coronary disease. * non-identified culprit lesion. * known allergy to aspirin, ticagrelor, prasugrel, clopidogrel, paclitaxel or sirolimus.

Keywords: stemi
economic evaluation of innovative molecular analyses in onco-haematology

Conditions: Haematological Malignancy

Summary: to evaluate the impact of innovative molecular diagnostics on the clinical management of patients with haematological malignancies via updated appropriate-prescribing-guides including next-generation sequencing (ngs) panels, facilitated therapeutic orientation, and optimised use of costly novel therapeutics and risk-adapted treatment. a micro-costing approach will be used to develop flat fee tarifs for ngs analyses.

the 12 somatic genetic cancer tests that have received temporary authorisation in france form the basis of this study. these tests are not yet in the national biology reimbursement nomenclature but are supported by the ministry of health in a temporary list "le référentiel des actes innovants hors nomenclature de biologie et d'anatomocytopathologie" (rihn). the prme rubih2 will focus on 5 clinical situations in onco-haematology: 1. myelodysplasia (mds) 2. acute lymphocytic leukemia (t) (all) 3. lymphoproliferative disorders (lpd) 4. acute myeloblastic leukemia (aml) 5. myeloproliferative disorders (mpd) the project is organised in 4 complementary work packages (wp): wp1 cost evaluation, wp2 prescription guidelines, wp3 clinical validation and wp4 budget impact and organisation. wp1 will provide costing information on molecular tests and will build on previous studies conducted in france. wp2 will update existing prescription guidelines based on evidence from the literature and evidence from the wp3. these prescription guidelines will in turn be valued and provide recommendations for a flat fee bundle for pre-specified clinical situations. wp3 will provide evidence on the clinical impact of molecular diagnosis (in particular ngs) in the 5 pre-specified conditions. changes in patient management will be measured using a prospective questionnaire for an estimated 3960 molecular tests. the impact of the test on the patient clinical pathway will be analysed. the impact of molecular tests on patient outcome will not be measured. wp4 will use information from wp1 and wp2 to estimate the budget impact and to provide scenario analyses on the territorial organisation of molecular biology platforms. based on the estimation of the national activity of molecular onco-haematology platforms the annual functioning budget required to implement molecular diagnosis in france will be estimated.

Eligibility criteria:
inclusion criteria: * patients with haematological malignancies referred for molecular diagnosis workup. rubih2 will focus on 5 clinical situations in onco-haematology: 1. myelodysplasia (mds) 2. acute lymphocytic leukemia (t) (all) 3. lymphoproliferative disorders (lpd) 4. acute myeloblastic leukemia (aml) 5. myeloproliferative disorders (mpd) exclusion criteria: * other haematological diseases not included in the list above.
association of force distribution and bone resorption

Conditions: Bone Resorption

Summary: to investigate the residual ridge resorption at anterior and posterior maxillary and posterior mandibular ridges among conventional complete dentures and implant overdenture wearers, and determine its association with the relative occlusal forces distribution, treatment groups and other patient variables.

a total of forty-six edentulous patients participated in this clinical study divided into two groups as following; complete denture group (cd) consists of 23 patients wearing conventional complete dentures and another implant overdenture group (iod) consists of 23 patients wearing mandibular complete overdenture with 2 implants. two panoramic radiographs at baseline and in a follow-up to 7 years were used to measure the ratio of bone changes between the anatomical bone area and the reference area in the maxillary and the mandibular ridges. the occlusal contacts percentage of force in maximum intercuspation anteriorly and posteriorly were recorded for both groups by using t-scan iii system. oral and written information in english or malay language, regarding the study, was provided and written consent obtained before enrolment.

Eligibility criteria:
inclusion criteria: * patients wearing mandibular iods opposing conventional maxillary cds. * patients wearing conventional maxillary and mandibular cds. * clearly visible anatomic landmarks of the panoramic radiography image. exclusion criteria: * patients with a history of temporomandibular joint dysfunction.
isis 2503 in treating patients with advanced cancer of the pancreas

Conditions: Pancreatic Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of isis 2503 in treating patients who have advanced cancer of the pancreas.

objectives: i. determine the response rate and time to progression in patients with advanced adenocarcinoma of the pancreas who are treated with isis 2503. ii. determine the duration of response in these patients receiving this regimen. iii. characterize the safety profile of isis 2503 at the recommended phase ii dose and schedule in these patients. outline: patients receive isis 2503 iv continuously for 14 days. treatment continues every 21 days for a minimum of 3 courses in the absence of unacceptable toxicity or disease progression. projected accrual: a total of 14-27 patients will be accrued for this study within 12 months.

Eligibility criteria:
disease characteristics: histologically confirmed advanced adenocarcinoma of the pancreas that is considered inoperable measurable disease with at least 1 lesion measuring at least 2 cm in widest diameter identifiable on ct or mri scan patient characteristics: age: 18 and over performance status: ecog 0-1 life expectancy: not specified hematopoietic: absolute neutrophil count greater than 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin no greater than 2.0 mg/dl renal: creatinine no greater than 2.0 mg/dl other: not pregnant or nursing negative pregnancy test fertile patients must use effective barrier contraception during and for 6 months after study no underlying disease state associated with active bleeding no active infection requiring therapy no other prior malignancy within the past 5 years except nonmelanoma skin cancer prior concurrent therapy: biologic therapy: no concurrent biologic therapy for pancreatic cancer chemotherapy: no prior chemotherapy for pancreatic cancer except for fluorouracil and/or gemcitabine administered as a radiosensitizer no other concurrent chemotherapy for pancreatic cancer endocrine therapy: not specified radiotherapy: prior radiotherapy allowed provided indicator lesions not within prior radiation port recovered from toxicity no concurrent radiotherapy for pancreatic cancer surgery: see disease characteristics other: no concurrent anticoagulation therapy with heparin no other concurrent approved or experimental cancer therapy

Keywords: stage iii pancreatic cancer adenocarcinoma of the pancreas stage iv pancreatic cancer